Haemonetics

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Haemonetics reports robust Q1 earnings, eyes U.S. growth amid challenges

Haemonetics delivered strong financial performance in Q1 fiscal 2023, driven by robust revenue growth in both the Plasma and Hospital segments. The company's focus on the U.S. market and plans for accelerating growth indicate a positive outlook. However, challenges related to potential cuts in donor payments and varying market conditions outside the U.S. require careful navigation.

Haemonetics Corporation reports robust Q1 fiscal 2024 performance and eyes international expansion

Haemonetics Corporation delivered impressive Q1 fiscal 2024 results, driven by strong revenue growth and improved operating income. The company faces challenges in managing inventory replenishment and potential competition in the autoimmune space. However, opportunities lie in leveraging its robust product portfolio and expanding into international markets.

Haemonetics reports strong Q3 performance, eyes European expansion for growth

Haemonetics delivered robust financial results in Q3, driven by strong revenue growth and strategic initiatives. While facing challenges related to staffing and donor issues, the company is well-positioned to leverage opportunities in expanding markets and technological advancements to drive future growth.

Haemonetics posts robust earnings, eyes global expansion for growth

Haemonetics delivered strong financial results in Q4 2023 and fiscal '23, driven by robust revenue growth and improved earnings per share.
The company's focus on key segments like Plasma, Hospital, Hemostasis, and Vascular Closure positions it well for future growth and market expansion.
While facing challenges such as cost pressures and competitive landscapes, Haemonetics remains optimistic about its ability to drive profitability and market share.
Strategic initiatives, including a modest ramp in market resources and international expansion, present opportunities for Haemonetics to capitalize on market demand and enhance shareholder value.

Haemonetics excels in Q1 '24, eyes growth amid challenges

Haemonetics delivered robust financial performance in Q1 '24, with significant revenue growth and margin expansion.
While facing challenges like product recalls, the company remains focused on value creation and growth acceleration strategies.
Opportunities for growth exist through market scaling, product innovations, and leveraging trial implications for demand growth.

Haemonetics posts robust Q2 earnings, eyes U.S. and international growth

Haemonetics reported strong Q2 results with increased earnings and revenue growth. The company's strategic acquisitions and focus on innovation position it well for future expansion. Challenges in the Blood Center segment require attention, but overall, Haemonetics is poised for continued growth.

Haemonetics posts robust Q3 earnings, eyes growth through innovation

Haemonetics delivered strong financial performance in Q3 2024, driven by revenue growth and operational efficiency improvements.
The company's focus on innovation, technology enhancements, and strategic acquisitions positions it well for future growth and market leadership.
While facing challenges in certain revenue segments, Haemonetics remains poised to capitalize on opportunities for expansion and margin improvement.

Haemonetics posts robust Q4 results, eyes growth through acquisitions

Haemonetics' Q4 2024 performance reflects strong revenue growth and profitability, driven by successful product launches and acquisitions.
While the company faces challenges in margin targets and integration post-acquisitions, strategic focus on innovation and market expansion presents growth opportunities.
Emphasis on non-GAAP measures and regulatory clearances underscores Haemonetics' commitment to transparency and product quality.
Fiscal year 2025 guidance signals a positive outlook for revenue growth and operational efficiency, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.

BOSTON, Jan. 5, 2021 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2021 financial results at 6:00 am EDT on Tuesday, February 2, 2021. The Company will hold a conference call with investors and analysts to...

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2021 Results: February 2, 2021

International Consolidated Airlines Group SA

SSE PLC

Vulcan Materials

With the Covid vaccine rollout accelerating, these companies will be big beneficiaries in the year ahead.

6 Stocks Set To Soar In 2021

Haemonetics has sustainable growth levers in place that are underscored by key product offerings and recent liquidity preservation measures. The company remains insulated from larger names via their extended service model that enables greater penetration in end-markets.

Haemonetics: Sustainable Growth Levers In Place, Above-Market Growth Opportunity

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock?

Haemonetics (HAE) Up 14.6% Since Last Earnings Report: Can It Continue?

We believe that Haemonetics stock, best known for its blood and plasma supplies and services, is a good buying opportunity at the present time. HAE stock trades near $113 currently and it is, in fact, down 7% from its pre-Covid high of $122 in February 2020 – just before the coronavirus.

Despite A 50% Rally Haemonetics Has More Upside

Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.

Haemonetics (HAE) New Products Aid, Plasma Sales Remain Tepid

Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an individual investor's stock selection process, as it may offer great insights of how the brightest minds of the finance industry feel about specific stocks. After all, these people have access to smartest analysts and expensive data/information sources that individual investors can't match. So should one consider investing in Haemonetics Corporation (NYSE:HAE)? The smart money sentiment can provide an answer to this question.

Was The Smart Money Right About Loading Up On Haemonetics Corporation (HAE)?

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down

Haemonetics Corporation (HAE) CEO Chris Simon on Q2 2021 Results - Earnings Call Transcript

  Shares of Haemonetics (NYSE:HAE) fell 0.1% in pre-market trading after the company reported Q2 results.

Haemonetics: Q2 Earnings Insights

BOSTON, Nov. 4, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal 2021, which ended September 26, 2020, are available on its Investor Relations website. In addition, the Company is also posting the earnings release and...

Haemonetics 2nd Quarter Fiscal Year 2021 Earnings Release Available on Investor Relations Website

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Haemonetics (HAE) Q2 Earnings Expected to Decline

BOSTON, Oct. 6, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednesday, November 4, 2020. The Company will hold a conference call with investors and analysts to...

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2021 Results: November 4, 2020

BOSTON, Oct. 2, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance...

Haemonetics Receives FDA Clearance For NexSys PCS® With Persona™ Technology

Cigna

Horizon Pharma

Vertex Pharmaceuticals

BioXcel Therapeutics

With the third quarter of what has proven to be a remarkable 2020 coming to a close, many of the firms we cover across Wall Street already are looking to the stretch run of the year and at what should be an improving 2021 economy as we emerge from the COVID-19 pandemic restrictions.

5 Jefferies High-Conviction Health Care Stocks May Be Huge Q4 Winners

BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, Sept.

Haemonetics To Present At The 18th Annual Morgan Stanley Global Healthcare Conference

Haemonetics (HAE) Up 18.4% Since Last Earnings Report: Can It Continue?

Shares of blood transfusion and plasma provider Haemonetics Inc. HAE, +2.34% were off their highs on Monday, after Needham analysts said news of an emergency use authorization for convalescent plasma as a treatment for hospitalized COVID-19 patients would not have a material impact on the company's plasma business.

Shares of plasma provider Haemonetics off highs as Needham says COVID-19 EUA not material to results

Haemonetics Corporation (HAE) CEO Chris Simon on Q1 2020 Results - Earnings Call Transcript

BOSTON, Aug. 7, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced it will present results of its IMPACT (IMproving PlasmA CollecTion) study.

Haemonetics Clinical Study Results On A New, Personalized Approach To Plasma Collection To Be Presented At 2020 AABB Annual Meeting

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down

Shares of Haemonetics (NYSE:HAE) moved higher by 0.1% in pre-market trading after the company reported Q1 results.

Haemonetics: Q1 Earnings Insights

Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline

BOSTON, July 24, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its wholly-owned.

Haemonetics Announces Sale Of Inlog Holdings France SAS To Abénex Capital

Amgen

Moderna

Netflix

Increasingly, the Wall Street firms we cover agree that while the future is still bright for the U.S.

News for Haemonetics Stock (HAE)